Influence of Hospitalization and Placebo Therapy on Blood Pressure and Sympathetic Function in Essential Hypertension
Overview
Authors
Affiliations
The decline in blood pressure (BP) in essential hypertensives following hospitalization may result from: 1) regression toward the mean; 2) reduction of anxiety as patients habituate to a new environment; 3) the placebo effect of medication; and 4) an independent effect of hospitalization itself. A randomized crossover study of 12 essential hypertensives demonstrated a fall in supine blood pressure from 165.0/97.9 +/- 2.3/1.1 mm Hg to 154.3/89.6 +/- 2.7/1.1 mm Hg (p less than 0.005) due to hospitalization. A similar reduction in BP from 164.9/99.5 +/- 8.4/4.1 mm Hg to 151.9/93.4 +/- 4.5/1.9 mm Hg (p less than 0.005) resulted from regression toward the mean and habituation during the study period. Urinary catecholamines fell from 68.7 +/- 5.0 to 55.1 +/- 4.3 micrograms/g creatinine/24 hours (p less than 0.05) due to hospitalization and from 56.1 +/- 5.4 to 49.7 +/- 4.3 micrograms/g creatinine/24 hours (p less than 0.05) with time. Although placebo therapy tended to reduce BP, it failed to do so significantly. When expressed as a percentage of the individual's overall mean, urinary catecholamine excretion fell from 110.5% +/- 3.7% to 89.5% +/- 3.7% (p less than 0.001) during hospitalization and from 105.8% +/- 3.9% to 94.2% +/- 3.9% (p less than 0.05) during the outpatient period. Blood pressure and sympathetic activity rapidly returned to prehospitalization values on discharge. These factors may confound the analysis of drug effects on BP and sympathetic activity in essential hypertensives following admission to hospital.
Haflidadottir S, Juhl C, Nielsen S, Henriksen M, Harris I, Bliddal H Trials. 2021; 22(1):493.
PMID: 34311793 PMC: 8314506. DOI: 10.1186/s13063-021-05454-8.
Cappelleri C, Janoschka A, Berli R, Kohler S, Braun-Dullaeus R, Heuss L Medicine (Baltimore). 2017; 96(34):e7692.
PMID: 28834872 PMC: 5571994. DOI: 10.1097/MD.0000000000007692.
Iuchi H, Sakamoto M, Suzuki H, Kayama Y, Ohashi K, Hayashi T PLoS One. 2016; 11(1):e0144921.
PMID: 26731185 PMC: 4701465. DOI: 10.1371/journal.pone.0144921.
Placebo interventions for all clinical conditions.
Hrobjartsson A, Gotzsche P Cochrane Database Syst Rev. 2010; (1):CD003974.
PMID: 20091554 PMC: 7156905. DOI: 10.1002/14651858.CD003974.pub3.
Meissner K, Distel H, Mitzdorf U BMC Med. 2007; 5:3.
PMID: 17371590 PMC: 1847831. DOI: 10.1186/1741-7015-5-3.